Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
- Eli Lilly 近 90 天出现 12 次
- 上一次：同一天稍早 · Eli Lilly is partnering with China's InnoCare on a drug deal worth up to $3.35 billion
发生了什么
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
摘要按规则整理自下方来源原文